A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer
1996

5-Fluorouracil with or without Interferon Alpha-2a in Advanced Colorectal Cancer

Sample size: 142 publication Evidence: moderate

Author Information

Author(s): A Piga, S Cascinu, L Latini, M Marcellini, M Bavosi, L Acito, R Bascioni, L Giustini, G Francini, A Pancotti, G Rossi, M Del Papa, F Carle, R Cellerino

Primary Institution: University of Ancona

Hypothesis

Does the addition of interferon alpha-2a to a weekly 5-fluorouracil regimen improve effectiveness while maintaining acceptable toxicity?

Conclusion

The addition of interferon to 5-fluorouracil did not improve efficacy compared to 5-fluorouracil alone.

Supporting Evidence

  • Response rates were 12.5% for 5-FU alone and 8.7% for 5-FU with interferon.
  • Progression-free survival and overall survival were identical in both treatment arms.
  • Toxicity was almost absent in the 5-FU alone group and moderate in the 5-FU with interferon group.

Takeaway

This study tested if adding a drug called interferon to a cancer treatment helped patients more than just using the treatment alone, but it didn't make a difference.

Methodology

Patients with advanced colorectal cancer were randomized to receive either 5-FU alone or 5-FU with interferon, with responses evaluated every 3 months.

Limitations

The study was stopped early due to low response rates and the addition of interferon not showing clinical benefit.

Participant Demographics

Of 141 eligible patients, 88 were male and 53 female, with a median age of 62 years.

Statistical Information

Confidence Interval

95% CI for response difference: -8.4% to 16.0%

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication